Danielli et al. reviewed cases of melanoma patients who received Tα1 in a phase II trial and the expanded access program by comparing the mOS of patients who received sequential anti-CTLA-4 inhibitors and Tα1 to assess combination therapy in long-term survivors. Here, CTLA4 is linked to melanoma.